diabetestalk.net

Toujeo Diabetes

(insulin Glargine Injection) 300 Units/ml

(insulin Glargine Injection) 300 Units/ml

Do not take Toujeo® if you have low blood sugar or if you are allergic to insulin or any of the ingredients in Toujeo®. Do NOT reuse needles or share insulin pens even if the needle has been changed. Before starting Toujeo®, tell your doctor about all your medical conditions, including if you have liver or kidney problems, if you are pregnant or planning to become pregnant or if you are breastfeeding or planning to breastfeed. Continue reading >>

What Is Toujeo®?

What Is Toujeo®?

Prescription Toujeo® is a long-acting insulin used to control blood sugar in adults with diabetes mellitus. Toujeo® contains 3 times as much insulin in 1 mL as standard insulin (100 Units/mL) Toujeo® is not for use to treat diabetic ketoacidosis Toujeo® should not be used in children If you are a patient experiencing problems with a Sanofi US product, please contact Sanofi US at 1-800-633-1610. The health information contained herein is provided for general educational purposes only. Your healthcare professional is the single best source of information regarding your health. Please consult your healthcare professional if you have any questions about your health or treatment. *This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, TRICARE, or similar federal or state programs, including any state pharmaceutical programs. Please note: the Federal Employee Health Benefits (FEHB) Program is not a federal or state government health care program for purposes of this savings program. Void where prohibited by law. For the duration of the program, the Savings Card carries maximum savings up to: $500 per pack for all patients who are enrolled in a commercial insurance plan, whether Toujeo® or Lantus® is covered or not by your insurance $200 per pack of Toujeo® for patients not enrolled in a commercial insurance plan, or in the FEHB Program $100 per pack of Lantus® for patients not enrolled in a commercial insurance plan, or in the FEHB Program This offer is valid for up to 3 packs per prescription. Savings may vary depending on patients’ out-of-pocket costs. Upon registration, patients receive all program details. Sanofi US reserves the right to change the maximum cap amount, rescind, revoke, or amend the p Continue reading >>

Insulin Glargine Injection For Subcutaneous Use

Insulin Glargine Injection For Subcutaneous Use

TOUJEO (insulin glargine) Injection DESCRIPTION TOUJEO (insulin glargine injection) is a long-acting insulin supplied as a sterile solution for subcutaneous injection containing 300 Units/mL of insulin glargine. Insulin glargine is a human insulin analog produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli (K12) as the production organism. Insulin glargine differs from human insulin in that the amino acid asparagine at position A21 is replaced by glycine and two arginines remain at the C-terminus of the B-chain. Chemically, insulin glargine is 21A-Gly-31B -32B -Di-Arg -human insulin and has the empirical formula C267H404N72O78S6 and a molecular weight of 6063. Insulin glargine has the following structural formula: Each milliliter of TOUJEO contains 300 Units (10.91 mg) insulin glargine dissolved in a clear aqueous fluid. The 1.5 mL SoloStar disposable prefilled pen presentation contains the following inactive ingredients per mL: 90 mcg zinc, 2.7 mg m-cresol, 20 mg glycerol 85%, and water for injection. The pH is adjusted by addition of aqueous solutions of hydrochloric acid and sodium hydroxide. TOUJEO has a pH of approximately 4. At pH 4, insulin glargine is completely soluble. After injection into the subcutaneous tissue, the acidic solution is neutralized, leading to formation of a precipitate from which small amounts of insulin glargine are slowly released. Continue reading >>

Diabetes Management Videos

Diabetes Management Videos

Remember to talk with your healthcare provider about how to inject before you begin using your pen. Review all of the instructions before using your pen. If you do not follow all of these instructions, you may get too much or too little insulin. GAIL: If youre going to be using a new Toujeo SoloStar pen, take it out of the refrigerator at least 1 hour before use to let it warm up. Ive found that cold insulin can be painful to inject. Before I begin, I always make sure that I have the correct insulin by checking the name of the insulin on the label of my pen. If you use other injector pens, it is especially important to confirm you have the correct medicine. KATHY: Also, check the label for the expiration date. Do not use your pen if its after the expiration date. GAIL: First, make sure your hands are clean, and then pull off the pen cap. Take a look at the insulin inside the pen to see if it is clear. KATHY: Dont use the pen if the insulin looks cloudy, colored, or contains particles. If you see any of these, use a new pen. GAIL: Next, wipe the rubber seal at the end of the pen with an alcohol swab. Now you are ready for the next step. There are a few things to remember before we show you how to attach the needle. Do NOT reuse needles. Be sure to always use a new, sterile needle for each injection. This helps stop blocked needles, contamination, and infection. Always use needles from BD (such as BD Ultra-Fine), Ypsomed (such as Clickfine) or Owen Mumford (such as Unifine Pentips). GAIL: First, take a new needle and peel off the protective seal. Hold the needle so its straight, and then screw it onto the pen. Be careful not to overtighten it. Next, pull off the outer needle cap and put it to the sideyoull need it after you have finished injecting. Then pull off the inne Continue reading >>

What Is Toujeo (insulin Glargine)?

What Is Toujeo (insulin Glargine)?

Toujeo is a brand name for the medicine insulin glargine, available in a prefilled injectable pen (SoloStar). It's used to treat people with type 1 diabetes (the body doesn't produce the hormone insulin) and type 2 diabetes (the body doesn't make or use insulin normally). Toujeo is a long-acting form of insulin that works by helping your body use sugar properly. For people with type 1 diabetes, Toujeo must be used with another type of insulin known as a short-acting insulin. People with type 2 diabetes may use other types of insulin or oral drugs along with Toujeo. Taking this prescription medicine along with adopting a healthy lifestyle can decrease your risk of developing serious or life-threatening complications, which may include heart disease, stroke, nerve damage from neuropathy, kidney problems, or eye issues. The Food and Drug Administration (FDA) approved Toujeo in 2015. It's marketed by Sanofi. Toujeo Warnings Toujeo shouldn't be used to treat diabetic ketoacidosis, a dangerous condition that can occur if high blood sugar is untreated. Before using Toujeo, tell your doctor if you have or have ever had: Diabetic neuropathy Heart, liver, or kidney disease Hypokalemia (low potassium levels in the blood) A severe allergic reaction (anaphylaxis) to any medicines, especially insulin products Toujeo shouldn't be used in children, and it should be used with caution in elderly people. Be sure to let your physician know that you're taking Toujeo before having any type of surgery, including a dental procedure. Your healthcare provider may recommend that you follow a specific diet and exercise plan while using Toujeo. Follow your doctor's instructions carefully. Illnesses, injuries, or unusual stress can affect your blood sugar levels. Talk to your physician if you experi Continue reading >>

Toujeo (insulin Glargine)

Toujeo (insulin Glargine)

Toujeo, which came to market in early 2015, is a form of man-made insulin known as insulin glargine. There are two other brands of insulin glargine on the market: Lantus (also made by Sanofi Aventis) and Basaglar (produced by Eli Lilly). Toujeo is intended to lower high blood sugar and A1c levels in people with type 1 and type 2 diabetes. Although Toujeo and Lantus are both insulin glargine and produced by the same company, Toujeos formulation makes it a more concentrated form of this medication. One milliliter of Toujeo contains three times as much insulin as Lantus. The higher concentration means that patients can inject a lower volume of insulin. This basal insulin works by forming crystals inside the body, which gradually dissolve and release small amounts of insulin into the bloodstream over the course of 24 hours or longer (up to 36 hours). This mimics the action of the pancreas and this slow and steady release has been proven to lower A1c levels significantly. Some people have been able to reduce or eliminate other oral diabetes medications while taking Toujeo and were still able to achieve their target A1c goals. Unlike most other insulins, Toujeo has no pronounced peak and it doesnt wear off between doses. It does take several hours to take effect, however. Its onset is approximately six hours after injection, as opposed to the 1-2 hours for Lantus. This extended onset helps to lower the incidence of hypoglycemia (low blood sugar). Toujeo should be used once a day, at the same time every day. Its also important to note that it can take five to eight days of daily dosing to reach a functional concentration in the body, according to Healthline . Toujeo is used to treat type 1 diabetes in adults and in children no younger than six years old. It is also used to tr Continue reading >>

Toujeo For The Treatment Of Type 1 And Type 2 Diabetes

Toujeo For The Treatment Of Type 1 And Type 2 Diabetes

Toujeo was compared to once-daily Lantus, another insulin injection, in Phase III clinical trials. Image: courtesy of Sanofi. Sanofi also manufactures medical devices for diabetes including blood glucose monitoring systems. Image: courtesy of Sanofi. Toujeo (insulin glargine [rDNA origin]) is an insulin injection approved for the treatment of type 1 and type 2 diabetes to improve glycaemic control in adult patients. The drug was discovered and developed by Sanofi. Toujeo was approved by US Food and Drug Administration (FDA) as a once-daily long-acting basal insulin to improve the glycaemic index in patients suffering from type 1 and type 2 diabetes in February 2015. A new drug application (NDA) of the drug was accepted for review by the FDA in July 2014 following acceptance of the marketing authorisation application by the European Medicines Agency (EMA) for EU countries in May 2014. The marketing authorisation request of Toujeo is under review with EMA and other health authorities worldwide. The drug is expected to be available in the US in the second quarter of 2015, subject to approval. Glycaemic control in type 1 and type 2 diabetics "Toujeo was approved by US Food and Drug Administration (FDA) as a once-daily long-acting basal insulin to improve the glycaemic index in patients suffering from type 1 and type 2 diabetes in February 2015." In both cases, glycaemic control plays a crucial role as it involves maintaining normal blood sugar levels in patients with diabetes mellitus. Good glycaemic control is an important part of diabetes care as both hyperglycaemia (elevated blood sugar levels) and hypoglycaemia (low blood sugar) may lead to chronic complications of diabetes. Toujeo’s mechanism of action Toujeo contains an active ingredient called insulin glargine whos Continue reading >>

Insulin Glargine Injection For Subcutaneous Use

Insulin Glargine Injection For Subcutaneous Use

Toujeo (insulin glargine) Injection is along-acting insulin indicated to improve glycemic control in adults with diabetes mellitus. Common side effects of Toujeo include: cold symptoms upper respiratory tract infection allergic reactions injection site reactions itching rash swelling of extremities, and weight gain The recommended starting dose of Toujeo in insulin na�ve patients with type 1 diabetes is approximately one-third to one-half of the total daily insulin dose. The remainder of the total daily insulin dose should be given as a short-acting insulin and divided between each daily meal. As a general rule, 0.2 to 0.4 units of insulin per kilogram of body weight can be used to calculate the initial total daily insulin dose in insulin na�ve patients with type 1 diabetes. The recommended starting dose of Toujeo in insulin na�ve patients with type 2 diabetes is 0.2 units per kilogram of body weight once daily. Toujeo may interact with other antidiabetic drugs, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blocking agents (ARBs), disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors (MAOIs), pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs, sulfonamide antibiotics, antipsychotics, corticosteroids, danazol, diuretics, estrogens, glucagon, isonazid, niacin, oral contraceptives, phenothiazines, progestogens, protease inhibitors, somatropin, sympathomimetic drugs, thyroid hormones, alcohol, beta-blockers, clonidine, lithium salts, clonidine, guanethidine, and reserpine. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Toujeo. Insulin requirements may change during pregnancy. It is unknown if Toujeo passes into breast m Continue reading >>

What It's Really Like Using New Basal Insulin Toujeo

What It's Really Like Using New Basal Insulin Toujeo

News came early in the year about Sanofi’s new basal insulin called Toujeo, which is a higher concentration than the long-established Lantus. You may remember hearing rumors about this insulin years ago while it was still in development, when Sanofi execs were trying to pinpoint a final name. At the time, U-300 was the code name and many referred to it as “the son of Lantus” in diabetes water-cooler chatter. The FDA approved Toujeo in February, and as of April, you can now get the new insulin in a familiar pre-filled, disposal pen that is labeled SoloStar just like its predecessor. Except the insulin is of course different. Toujeo has that higher concentration (U-300 instead of the standard U-100 we’ve been used to for so long), so patients can inject less volume, and it has an extended onset of action (6 hours vs. Lantus' 1.1 hours) that can help reduce risk of hypoglycemia. One analogy Sanofi has suggested is to think of their two insulins like laundry detergent brands. Lantus is the traditional Tide in a pour-container, but Toujeo is like the contemporary pods that don’t require measuring for a single-wash. “Same cleaning power, but in a smaller delivery and higher concentration.” Sanofi has reworked the SoloStar pen, so that it “does the math for you," meaning it automatically translates the 300 units of insulin per millimeter vs. Lantus' 100 into the same number of pen dials as you'd see with Lantus. And their marketing boasts Toujeo's benefits: “Better than Lantus! Basal insulin lasts a full 24 hours! Fewer hypos!” Of course, they stand to win either way, since they also sell the competitor. An invite-only media webinar in mid-August included a Q&A session with Sanofi reps and diabetes educators on Toujeo. While it was mostly what you’d expec Continue reading >>

(insulin Glargine Injection) 300 Units/ml

(insulin Glargine Injection) 300 Units/ml

Do not take Toujeo® if you have low blood sugar or if you are allergic to insulin or any of the ingredients in Toujeo®. Do NOT reuse needles or share insulin pens even if the needle has been changed. Before starting Toujeo®, tell your doctor about all your medical conditions, including if you have liver or kidney problems, if you are pregnant or planning to become pregnant or if you are breastfeeding or planning to breastfeed. Continue reading >>

Toujeo Reduced Risk Of Severe Low Blood Sugar Compared To Insulin Glargine 100 Units/ml And Insulin Detemir

Toujeo Reduced Risk Of Severe Low Blood Sugar Compared To Insulin Glargine 100 Units/ml And Insulin Detemir

Toujeo reduced risk of severe low blood sugar compared to insulin glargine 100 Units/mL and insulin detemir VIENNA February 14, 2018 With the continued evolution in diabetes care and a growing understanding of todays insulin options, Sanofi is pleased to share new real-world evidence results which showed that Toujeo (insulin glargine 300 Units/mL) significantly reduced the risk of severe low blood sugar (hypoglycemia) events compared to the long-acting insulins, insulin glargine 100 Units/mL (Lantus) and insulin detemir. These data are being presented at the 11th Annual Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Vienna, Austria. New findings from LIGHTNING, the largest and most recent real-world comparative study involving more than 10,000 patients treated with long-acting insulins, found that Toujeo reduced the risk of severe low blood sugar events, defined as an event-related inpatient or emergency room visit for people with type 2 diabetes, by more than 60% compared to insulin glargine 100 Units/mL and insulin detemir. The data also showed that the risk of severe low blood sugar events were comparable between Toujeo and insulin degludec. The reduction of blood sugar levels were not compromised in any of the treatment arms. Further analyses are planned to correlate the findings with clinical and economic outcomes. The LIGHTNING study evaluated electronic medical records of 130,155 adult patients in the U.S. Optum-Humedica database who were treated with long-acting insulin. Using innovative statistical techniques, the study identified 10,458 adults with type 2 diabetes, with a majority of similar demographics and clinical characteristics, who switched from using any long-acting insulin to Toujeo, insulin glargine 100 Units/mL or insulin Continue reading >>

How Does Next-gen Basal Insulin Toujeo Work In Type 2 Diabetes?

How Does Next-gen Basal Insulin Toujeo Work In Type 2 Diabetes?

A real-world trial in 3,000+ participants currently enrolling participants with type 2 diabetes Clinical Trials Identifier: NCT02451137 Trial name: A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM) Diabetes type: Type 2 What the trial is testing: The aim of this study is to demonstrate the clinical benefit of Toujeo, Sanofi’s once-daily long-acting basal insulin, in comparison to other available basal insulins Levemir and Lantus (read more about basal insulins here). What the trial is measuring: After six months, the trial will measure A1c levels and instances of documented hypoglycemia, defined as blood sugar levels less than 70 mg/dl in this study. Why this is important: Toujeo is currently approved for use in adults with diabetes as a daily basal insulin injection. Previous phase 3 clinical trials had shown that Toujeo is slightly better than Lantus in lowering A1c but with mixed results for reducing risk for hypoglycemia. (Compared to Lantus, which has 100 units of insulin glargine in each milliliter, Toujeo is more concentrated with 300 units of insulin per milliliter.) This real-world trial may provide more conclusive information on whether Toujeo has any hypoglycemia benefits. Trial length: Up to 53 weeks Trial location: 393 locations throughout the US and Canada, including San Diego, New York City, Dallas, and Miami. Visit this site and click the “Find A Location” tab to see the full list. Do you qualify? Diagnosed with type 2 diabetes for at least one year prior to screening An A1c between 8% and 11% Treatment with two or more of the following: metformin, sulfonylureas (Glucotrol, Amaryl, glyburide), TZDs (Avandia or Actos), DPP-4 inhibitors (Januvia, Onglyza, Tradjenta, etc), SGLT-2 inhibit Continue reading >>

(insulin Glargine Injection) 300 Units/ml

(insulin Glargine Injection) 300 Units/ml

If you are a patient experiencing problems with a Sanofi US product, please contact Sanofi US at 1-800-633-1610. The health information contained herein is provided for general educational purposes only. Your healthcare professional is the single best source of information regarding your health. Please consult your healthcare professional if you have any questions about your health or treatment. Continue reading >>

Toujeo As Effective As Tresiba In Reducing Blood Sugar, Study Reveals

Toujeo As Effective As Tresiba In Reducing Blood Sugar, Study Reveals

Toujeo as effective as Tresiba in reducing blood sugar, study reveals Toujeo as effective as Tresiba in reducing blood sugar, study reveals Oral semaglutide shows positive results compared to injectable version 18 October 2017 The diabetes drug Toujeo is as effective as Tresiba (insulin degludec) in terms of reducing blood sugar levels in people with type 2 diabetes , a study reports. Toujeo , a once-daily long-acting insulin made by the drug company Sanofi, was compared to Novo Nordisk's drug Tresiba in a trial called the BRIGHT study. Toujeo is also known as insulin glargine 300, and was approved as a diabetes treatment in the UK in early 2015. Researchers wanted to see whether Toujeo garnered the same results as Tresiba when it came to controlling HbA1c levels. They also wanted to see whether the drug reduced the number of people who experienced adverse events and low blood sugar levels. The initial findings of the BRIGHT trial, involving more than 900 people who had previously struggled to control their type 2 diabetes on non-insulin medication, have been positive. The full research paper will be published next year and will be needed to compare whether the rates of hypoglycemia were similar. Novo Nordisk's Tresiba has shown strong results in reducing nocturnal hypos in particular and it remains to be seen if Toujeo can compete with this. Sanofi's Riccardo Perfetti, head of the global diabetes medical, said: "The most recently introduced long-acting insulins have already demonstrated significant blood glucose lowering benefit to adult patients with diabetes. From the perspective of physicians and patients, hypoglycemia remains a major limiting factor in effective blood sugar management in diabetes. "We believe that these first comparative clinical data assessing si Continue reading >>

Lantus, Toujeo (insulin Glargine) Dosing, Indications, Interactions, Adverse Effects, And More

Lantus, Toujeo (insulin Glargine) Dosing, Indications, Interactions, Adverse Effects, And More

100 units/mL (Lantus SoloSTAR; Basaglar KwikPen; 3 mL disposable prefilled pens) 300 units/mL (Toujeo; 1.5 mL SoloStar disposable prefilled pen) 300 units/mL (Toujeo Max; 3 mL SoloStar disposable prefilled pen) Note: Recent studies have suggested that glargine-300 extends blood glucose control well beyond 24 hr Long-acting basal insulin indicated to improve glycemic control in adults with type 1 diabetes mellitus Start ~1/3 of total daily insulin dose; use remaining 2/3 of daily insulin dose on short-acting, premeal insulin Usual initial dose range: 0.2-0.4 units/kg; optimal glucose lowering effect may take 5 days to fully manifest and the first insulin glargine dose may be insufficient to cover metabolic needs in the first 24 hr of use Titrate insulin glargine per instructions, and adjust coadministered glucose-lowering therapies per standard of care See Dosing Considerations and Administration Long-acting basal insulin indicated to improve glycemic control in adults with type 2 diabetes mellitus Start 0.2 units/kg qDay; if necessary, adjust dosage of other antidiabetic drugs when starting insulin glargine to minimize the risk of hypoglycemia See Dosing Considerations and Administration Dose must be individualized based on clinical response; blood glucose monitoring is essential in all patients receiving insulin therapy Patients adjusting the amount or timing of dosage should do so only under medical supervision with appropriate glucose monitoring Titrate Toujeo dose no more frequently than every 3-4 days Use with caution in patients with visual impairment who may rely on audible clicks to dial their dose If changing from a treatment regimen with an intermediate- or long-acting insulin to a regimen with insulin glargine, the amount and timing of shorter-acting insulin Continue reading >>

More in diabetes